#vaccine research

Messenger RNA vaccines—also called mRNA vaccines—are some of the first COVID-19 vaccines authorized for use in the United States.

In the United States, an FDA expert advisory panel voted on December 10 to recommend emergency use authorization.

The vaccine from the University of Oxford and AstraZeneca uses a chimpanzee adenovirus vector.

With the first vaccines expected within weeks, a CDC advisory panel votes on how to prioritize access.

Moderna has requested emergency use authorization for its mRNA vaccine candidate.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

Vaccine development is proceeding at an unprecedented pace, but could still hit snags on the way to approval.

Upcoming hearing on the Pfizer/BioNTech vaccine will be livestreamed on YouTube, Facebook and Twitter.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.

A U.K. woman developed spinal inflammation after receiving an adenovirus vector vaccine.

Advocates claim victory after more than 1,000 people endorse a demand for inclusion.

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

People who received the vaccine did, however, show stronger immune responses against the virus.